From July 15 to 17, 2022, the ZAODX World Early Cancer Screening Conference, focusing on the research and development and transformation and application of global early screening cutting-edge technologies, was successfully held in Guangzhou. The conference focused on the three major perspectives of “world pattern”, “China exploration” and “solutions” , conduct in-depth discussions around the three major aspects of “technological power”, “productivity” and “market power”, build a top global communication platform, and help industries improve their global cooperation capabilities and market transformation and application capabilities of scientific and technological achievements.
Dr. Yu Chang, founder of Anpac Biotechnology, was invited to participate in a roundtable discussion at the “Multi-omics and Multi-Cancer Liquid Biopsy Frontier Forum” on July 15, and together with industry experts and scholars focused on “Multi-omics and Multi-Cancer” “Opportunities and Challenges of Liquid Biopsy” will be discussed as the core to jointly promote the development of the early cancer screening industry. At the same time as attending the meeting, Dr. Yu Chang also won the title of “Ingenuity Figure” of this year’s Golden Screen Award.
At the same time, Anpac Biotechnology, Dean Diagnostics, Exact Sciences and other companies were ranked jointly on the list of leading companies (listed) in the “Golden Screening Award” selection activity launched by Zaosifing.com, and were awarded the title of “Golden Screening Award·Leading Company” . Anpac Biotechnology has been deeply involved in the field of early cancer screening for more than 10 years with its profound scientific research strength. It has proposed innovative methodologies of “multiple (pan) cancers” and “multi-level, multi-parameter screening” and adopted innovative biophysical technologies for cancer applications. The practice of detection, and independently developed CDA technology with many advantages including multi-cancer, high cost-effectiveness, early detection, high sensitivity and high specificity, provide important ideas, innovative concepts and scientific and technological strength for the development of early cancer screening. This award is a high degree of recognition and praise for the achievements of Anpac Biotech.
As one of the first companies to propose innovative methodology and cancer detection concepts of “multi-cancer” and “multi-level, multi-parameter screening”, Anpac Biotech independently develops “cancer risk” based on the correlation between biophysical properties and cancer risk. Assessment (CDA)” technology to make risk assessments of the presence and likelihood of cancer. After years of research and development and practice, we have made progress in many aspects in the field of early cancer screening, and this innovative technology has benefited the public, saved human lives, successfully achieved localization, and occupied the commanding heights of technology.
Looking back on the innovation path of more than ten years, Anpac Biotech has never stopped working hard and has always advocated the innovative concept of multi-cancer screening: including reports on clinical trial results since the beginning of 2010 (including multiple ASCO paper publications), several Ten patent applications, disclosures and press releases covering multiple cancer screening claims in multiple countries. As of March 31, 2022, Anpac Biotechnology has applied for 260 patents in 20 countries and regions around the world, of which 155 have been authorized.
In terms of scientific research, Anpac Biotechnology has also been forging ahead. In November 2021, the team published an academic paper “A Review of New Cancer Screening Methods” in the well-known British journal “EXPERT REVIEW OF MOLECULAR DIAGNOSTICS” with a team from Shanghai Jiao Tong University School of Medicine and many other well-known medical institutions, with an impact factor of 5.223. In April 2022, Clinical trials and results of CDA technology used in lung cancer efficacy evaluation were announced at the AACR Annual Meeting of the American Association for Cancer Research.
In recent years, with the active promotion and collaboration of more and more peer companies, the innovative theory of multi-cancer screening has gradually been widely accepted by the industry. But what cannot be ignored is that Anpac Biotech from China started earlier and has gone further!
Frost & Sullivan (“Sullivan”), a well-known market analysis and research company, in a recent research report (based on data accumulation as of the end of January 2021) ranked Anpac Biotech as a global pan-(multiple) The No. 1 company in cancer screening and detection, including next-generation cancer screening and detection technologies, including circulating cancer cells (CTCs), circulating tumor DNA (ct-DNA), exosomes, cancer risk assessment (CDA), and mRNA and other emerging technologies. At present, the CDA technology platform jointly developed by Anpac Biotech and medical institutions can detect the risk of more than 20 types of cancer with its high sensitivity and specificity. As of March 31, 2022, Anpac Biotech has a large database in the global next-generation cancer early screening field, and has successfully completed the verification of more than 250,000 cases, and is still growing.
Healthy China, early screening first. In the past ten years, Anpac Biotechnology has been a concept leader in multi-cancer detection and a pioneer and advocate of innovative methodologies, making contributions to the concept, technology development and practice in this field. made significant contributions. In the future, Anpac Biotechnology will not forget its original intention, continue to uphold the beautiful vision of “keeping humans away from cancer”, delve into multi-cancer screening innovation, early cancer screening and treatment, and promote the rapid development of early cancer screening!
About Anpac Biotechnology
Anpac Biotechnology is a biotechnology company focused on early cancer screening and detection. As of March 31, 2022, it owned 155 patents. Anpac Biotech has two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States. A range of cancer screening and detection tests are available, including CDA (Cancer Risk Assessment Technology), biochemical, immunological and genomic testing. A market research report by Frost & Sullivan shows that Anpac Biotech ranks first in the world in terms of sample volume for multi-cancer screening and testing (cumulative as of January 2021). These clinical experiments show that Anpac Bio’s CDA technology and platform can detect the risk of more than 20 types of cancer with high sensitivity and specificity.
